Skip to content

Comparing two doses of Dexmedetomidine with ropivacaine for Cesarean section pain relief

Effect of intrathecal dexmedetomidine (3µg vs 5µg) as an adjuvant to hyperbaric ropivacaine in cesarean section: A randomized double blind clinical study - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/077026
Enrollment
126
Registered
2024-11-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O82- Encounter for cesarean delivery without indication

Interventions

Intervention1: ROPIVACAINE+3µg DEXMEDETOMIDINE: The spinal anesthesia procedure is performed under aseptic and antiseptic conditions. A 23-gauge needle is used to administer 2cc of ropivacaine heavy c

Sponsors

Government Medical College Baroda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age Group – 18 years to 40 years 2.ASA – I/II 3.Elective Caesarean section

Exclusion criteria

Exclusion criteria: 1.Patients Refusal 2.Multifetal pregnancy 3.Heart block & ventricular dysfunction 4.Patient on anticoagulant therapy 5.Patient with local site infection 6.Patients with allergy to study drugs 7.Fetal distress in utero. 8.Severe hypovolemia. 9.Severe operative blood loss expected. (Placenta Previa, Accrete etc.) 10.Height less than or equal to 150cm

Design outcomes

Primary

MeasureTime frame
1.Monitoring of spinal characteristics (sensory and motor blockade, satisfaction of spinal anesthesia, visceral traction response, the quality of abdominal muscle relaxation and shivering & sedation score) 2.Hemodynamic stability (intraoperative)Timepoint: Till 24hrs

Secondary

MeasureTime frame
1.Postoperative analgesia score (VAS SCORE) 2. Apgar score of neonatesTimepoint: Till 24hrs

Countries

India

Contacts

Public ContactJyotsna F Maliwad

Government Medical College Baroda

dr.mantujr@gmail.com9879541238

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026